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background:  Diabetes is associated with an increased risk of major adverse cardiac events (MACE) following percutaneous coronary 
intervention. In this substudy of the SORT OUT IV trial, we compared the 5-year clinical outcome among patient with and without diabetes 
mellitus treated with everolimus-eluting (EES) or sirolimus-eluting (SES). 
methods:  Of 2,774 patients, 390 (14.1%) patients had diabetes and were treated with EES (n=1,390, diabetes: n = 194) or SES (n = 
1,384, diabetics: n=196). Randomization was stratified by presence/absence of diabetes. MACE was defined as a composite of cardiac 
death, myocardial infarction (MI), definite stent thrombosis or target vessel revascularization.
results:  At 5-year follow-up MACE were higher among diabetic patients (diabetic patients: 21.8% vs. non-diabetic patients: 14.8%; 
Hazard ratio (HR) 95% confidence interval 1.57 (1.24-1.98)). At 5-year MACE was 17.0% in the EES and 26.5% in the SES-treated diabetic 
patients (HR 0.61 95% CI 0.39-0.94) and 13.6% in the EES and 15.9% in the SES-treated patients without diabetes (HR 0.85 95% CI 
0.69-1.05) (P-interaction 0.16). In diabetic patients cardiac death 8.2% in EES and 10.2% in SES-treated patients (HR 0.79 95% CI 0.41-
1.52) and MI 2.6% in EES- and 5.6% in SES-treated patients (HR 0.45 95% CI 0.16-1.29) did not differ between EES and SES treated 
patients. Clinically driven target lesion revascularization 4.6% in EES and 10.2% in SES-treated patients (HR 0.44 95% CI 0.20-0.97) 
was significantly lower in EES treated diabetic patients. Definite stent thrombosis was seen not seen in diabetic patients treated with EES 
compared to 4 patients treated with SES. Definite or probable stent thrombosis occurred in 2 and 5 patients respectively.
Conclusion:  In diabetic patients, EES was associated with a reduced risk of MACE compared to SES, which was mainly attributable to a 
reduced clinically driven target lesion revascularization rate.
